ALPHA TEKNOVA, INC. (TKNO) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$1.30M*; Operating income -$2.89M; Depreciation and amortization $1.59M*.
- 2026-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$2.43M*; Operating income -$4.02M; Depreciation and amortization $1.59M*.
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$1.30M* | -$2.89M | $1.59M* | $12.19M | -10.64%* | $125.00K* | -$471.00K* | $7.30M | $554.00K | (m) | $30.00K |
| 2026-03-31 | Reported | (m) | (m) | (m) | (m) | -24.57% | $221.00K | -$3.36M | $7.29M | $609.00K | (m) | $47.00K |
| 2025-12-31 | Reported | (m) | (m) | (m) | (m) | -30.33% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | Reported | -$2.43M* | -$4.02M | $1.59M* | $10.45M | -23.21%* | $387.00K* | -$1.98M* | $7.25M | $542.00K | (m) | $79.00K |
| 2025-06-30 | Reported | -$1.80M* | -$3.39M | $1.59M* | $10.29M | -17.46%* | $207.00K* | -$2.10M* | $6.30M | $581.00K | (m) | $19.00K |
| 2025-03-31 | Reported | (m) | (m) | (m) | (m) | -34.55% | $206.00K | -$4.10M | $6.79M | $552.00K | (m) | $22.00K |
| 2024-12-31 | Reported | (m) | (m) | (m) | (m) | -42.99% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | Reported | -$5.76M* | -$7.43M | $1.67M* | $9.58M | -60.16%* | $331.00K* | -$2.06M* | $9.49M | $627.00K | (m) | -$8.00K |
| 2024-06-30 | Reported | -$3.47M* | -$5.10M | $1.63M* | $9.61M | -36.13%* | $115.00K* | -$2.84M* | $6.81M | $678.00K | (m) | -$8.00K |
| 2024-03-31 | Reported | (m) | (m) | (m) | (m) | -68.35% | $112.00K | -$6.56M | $7.08M | $860.00K | (m) | -$34.00K |
| 2023-12-31 | Reported | (m) | (m) | (m) | (m) | -117.54% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | -$7.14M* | -$8.76M | $1.62M* | $8.17M | -87.40%* | $972.00K* | -$4.38M* | $6.70M | $1.40M | (m) | $9.00K |
| 2023-06-30 | Reported | -$5.70M* | -$7.00M | $1.30M* | $11.53M | -49.45%* | $2.34M* | -$3.86M* | $6.46M | $1.46M | (m) | $15.00K |
| 2023-03-31 | Reported | (m) | (m) | (m) | (m) | -85.69% | $4.31M | -$7.68M | $6.70M | $1.40M | (m) | -$18.00K |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -169.09% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | -$22.23M* | -$22.95M | $729.00K* | $10.69M | -207.87%* | $6.58M* | -$8.33M* | $5.92M | $1.93M | (m) | -$374.00K |
| 2022-06-30 | Reported | -$5.83M* | -$6.63M | $792.00K* | $11.69M | -49.91%* | $10.92M* | -$5.84M* | $6.44M | $1.93M | (m) | -$395.00K |
| 2022-03-31 | Reported | (m) | (m) | (m) | (m) | -45.68% | $5.92M | -$5.20M | $5.80M | $2.01M | (m) | -$359.00K |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | -39.41% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | -$3.14M* | -$3.89M | $748.00K* | $9.39M | -33.43%* | $3.91M* | -$4.84M* | $5.13M | $1.37M | (m) | -$892.00K |
| 2021-06-30 | Reported | -$1.83M* | -$2.53M | $700.00K* | $8.31M | -21.97%* | $4.67M* | -$3.55M* | $4.96M | $851.00K | (m) | -$583.00K |
| 2021-03-31 | Reported | (m) | (m) | (m) | (m) | -1.94% | $3.88M | $2.40M | $4.05M | $700.00K | (m) | -$165.00K |
| 2020-12-31 | Reported | (m) | (m) | (m) | (m) | 13.45% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | $2.69M* | $2.15M | $542.00K* | $8.98M | 29.99%* | $1.02M* | $1.77M* | $3.90M | $358.00K | (m) | $636.00K |
| 2020-06-30 | Reported | (m) | $704.00K | (m) | $6.04M | (m) | (m) | (m) | $2.58M | $341.00K | (m) | $211.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | (m) | (m) | (m) | -26.24% | $1.15M | -$8.65M | $27.08M | $2.20M | (m) | $58.00K |
| 2024-12-31 | Reported | (m) | (m) | (m) | (m) | -51.84% | $1.13M | -$12.39M | $30.51M | $2.76M | (m) | -$88.00K |
| 2023-12-31 | Reported | (m) | (m) | (m) | (m) | -81.52% | $7.93M | -$18.81M | $26.39M | $5.57M | (m) | -$298.00K |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -112.25% | $28.15M | -$27.40M | $23.94M | $7.74M | (m) | -$1.92M |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | -24.73% | $19.88M | -$9.07M | $19.27M | $4.31M | (m) | -$2.83M |
| 2020-12-31 | Reported | (m) | (m) | (m) | (m) | 21.43% | $5.47M | $2.50M | $13.54M | $1.51M | (m) | $1.16M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |